Literature DB >> 21617712

The INTER-ROMA project--a survey among Italian radiation oncologists on their approach to the treatment of bone metastases.

Berardino De Bari1, Silvia Chiesa, Andrea Riccardo Filippi, Maria Antonietta Gambacorta, Valentina D'Emilio, Paola Murino, Lorenzo Livi.   

Abstract

AIMS AND
BACKGROUND: Radiotherapy has an established palliative role for bone metastases but despite the large number of patients treated there is still controversy surrounding the optimal radiotherapy schedule to prescribe. The aim of this survey was to determine the decision patterns of Italian radiation oncologists in four different clinical cases of patients with bone metastases. METHODS AND STUDY
DESIGN: During the latest national meeting of the Italian Association of Radiation Oncology (AIRO), four clinical cases were presented to attending radiation oncologists. The cases were different with respect to the histology of the primary tumor, performance status, pain before and after analgesics, tumor site, and radiological characteristics of the metastatic lesions. For each clinical case the respondents were asked to give an indication for treatment; prescribe doses, volumes and treatment field arrangements; decide whether to prescribe prophylactic supportive therapy or not; and provide information about factors that particularly influenced prescription. Finally, a descriptive statistical analysis was performed.
RESULTS: Three hundred questionnaires were distributed to radiation oncologists attending the congress. One hundred twenty-five questionnaires were returned but only 122 (40.6%) were adequately completed and considered for the analysis. Considerable differences were observed among radiation oncologists in prescribing and delivering radiotherapy for bone metastases. There was also a notable divergence from international guidelines, which will be discussed in this report.
CONCLUSIONS: Despite the results of clinical trials, Italian radiation oncologists differ considerably in their decisions on treatment doses and volumes. National guidelines are needed in order that patients can be treated uniformly and better data will become available for evidence-based palliative radiotherapy.

Entities:  

Mesh:

Year:  2011        PMID: 21617712     DOI: 10.1177/030089161109700208

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  5 in total

1.  The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists.

Authors:  Pierfrancesco Franco; Patrizia Ciammella; Andrea Peruzzo Cornetto; Berardino De Bari; Michela Buglione; Lorenzo Livi; Filippo Alongi; Andrea Riccardo Filippi
Journal:  Med Oncol       Date:  2013-09-27       Impact factor: 3.064

Review 2.  Palliative radiotherapy for bone metastases from lung cancer: Evidence-based medicine?

Authors:  Alysa Fairchild
Journal:  World J Clin Oncol       Date:  2014-12-10

3.  A strategy for young members within national radiation oncology societies: the Italian experience (AIRO Giovani group).

Authors:  Andrea Riccardo Filippi; Filippo Alongi; Patrizia Ciammella; Berardino De Bari; Pierfrancesco Franco; Lorenzo Livi
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-19

4.  Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial) : First results of a randomized controlled trial.

Authors:  Tanja Sprave; Vivek Verma; Robert Förster; Ingmar Schlampp; Thomas Bruckner; Tilman Bostel; Stefan Ezechiel Welte; Eric Tonndorf-Martini; Rami El Shafie; Nils Henrik Nicolay; Jürgen Debus; Harald Rief
Journal:  Strahlenther Onkol       Date:  2018-07-05       Impact factor: 3.621

5.  Continuous controversy about radiation oncologists' choice of treatment regimens for bone metastases: should we blame doctors, cancer-related features, or design of previous clinical studies?

Authors:  Carsten Nieder; Adam Pawinski; Astrid Dalhaug
Journal:  Radiat Oncol       Date:  2013-04-10       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.